242 results on '"Brown, Jennifer R."'
Search Results
2. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib
3. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
4. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
5. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
6. Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia
7. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
8. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
9. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples
10. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
11. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
12. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia
13. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
14. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
15. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
16. COVID-19 vaccination during therapy in relation to COVID-19 death in CLL
17. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
18. Cardiovascular Toxicities Associated With Ibrutinib
19. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
20. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
21. CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)
22. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
23. CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
24. EXABS-179-CLL DEBATE: Sequencing Small Molecules Is the Way to Go
25. How I treat CLL patients with ibrutinib
26. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
27. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL
28. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
29. 169 - Chronic Lymphocytic Leukemia
30. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
31. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
32. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
33. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
34. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
35. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
36. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
37. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
38. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
39. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
40. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
41. Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens
42. Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner-City Population
43. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
44. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
45. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
46. CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
47. CLL-269 Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naïve Cohort in the Phase 1/2 BRUIN Study
48. Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
49. Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naïve Cohort in the Phase 1/2 BRUIN Study
50. Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.